Compare RIVN & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIVN | DGX |
|---|---|---|
| Founded | 2009 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 23.1B |
| IPO Year | 2021 | 1996 |
| Metric | RIVN | DGX |
|---|---|---|
| Price | $15.93 | $195.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 13 |
| Target Price | $17.89 | ★ $208.62 |
| AVG Volume (30 Days) | ★ 20.8M | 648.6K |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.76% |
| EPS Growth | ★ 34.54 | 13.78 |
| EPS | N/A | ★ 8.75 |
| Revenue | $5,387,000,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $33.90 | $7.55 |
| Revenue Next Year | $63.73 | $3.75 |
| P/E Ratio | ★ N/A | $22.38 |
| Revenue Growth | 8.39 | ★ 11.78 |
| 52 Week Low | $10.36 | $157.20 |
| 52 Week High | $22.69 | $213.50 |
| Indicator | RIVN | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 39.05 |
| Support Level | $15.73 | $176.61 |
| Resistance Level | $16.17 | $197.55 |
| Average True Range (ATR) | 0.82 | 4.12 |
| MACD | 0.08 | -1.84 |
| Stochastic Oscillator | 48.98 | 3.93 |
Rivian is a battery electric vehicle automaker that sells its vehicles in the US and Canada. The company also develops electronic control units and related software for autos in a joint venture with Volkswagen. Rivian has multiple vehicles in its fleet, which include a luxury truck and full-size SUV and a delivery van. The company also plans to begin selling a midsize SUV in 2026. Total deliveries were nearly 52,000 in 2024. Rivian is also developing autonomous driving software to be used in its vehicles.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.